Table 1.

Clinical Characteristics for all men and by ERG overexpression status among 1,180 men treated with radical prostatectomy for prostate cancer^a, PHS and HPFS cohorts 1983-2011

Characteristic	All Men	ERG Negative	ERG Positive	% ERG Positive	Pb
Number	1,180	596	584	49%
Mean Follow-Up Time (years ± SD)	12.6 ± 4.5	12.2 ±4.2	13.0 ±4.7	-	<0.01
Mean Age at Diagnosis (years ± SD)	65.4 ± 5.9	65.6 ±5.9	65.2 ±5.9	-	0.17
Pathological Tumor Stage
T2 N0/Nx	818 (72%)	430 (75%)	388 (68%)	47%
T3 N0/Nx	290 (25%)	130 (23%)	160 (28%)	55%
T4/N1/M1	34 (3%)	12 (2%)	22 (4%)	65%	<0.01
Gleason Sum
2−6	256 (22%)	135 (23%)	121 (21%)	47%
3+4	438 (37%)	204 (34%)	234 (40%)	53%
4+3	268 (23%)	143 (24%)	125 (21%)	47%
8−10	218 (18%)	114 (19%)	104 (18%)	48%	0.58
PSA-Level at Diagnosis
<4	132 (12%)	56 (10%)	76 (14%)	58%
4-<10	641 (60%)	322 (60%)	319 (60%)	50%
≥10	293 (27%)	160 (30%)	133 (25%)	45%	0.02
Lethal Prostate Cancer c
No	1,095 (93%)	553 (93%)	542 (93%)	50%
Yes	85 (7%)	43 (7%)	42 (7%)	49%	0.99
Biochemical Recurrence
No	914 (77%)	462 (78%)	452 (77%)	49%
Yes	266 (23%)	134 (22%)	132 (23%)	50%	0.96
All Cause Mortality d
No	869 (74%)	435 (73%)	434 (74%)	50%
Yes	311 (26%)	161 (27%)	150 (26%)	48%	0.60

Abbreviations: PSA – Prostate Specific Antigen; SD – Standard Deviation

^aNumbers may not add up to 1,180 because men with missing information for a characteristic are not included in that characteristic

^bP-values are based on t-test for follow-up time and age at diagnosis; Cochran-Armitage trend test for tumor stage, Gleason sum, and PSA-level at diagnosis; Chi-square test for lethal prostate cancer, biochemical recurrence, and all cause mortality

^cLethal prostate cancer includes metastases to distant organs or bone, and prostate cancer death

^dAll cause mortality includes prostate cancer death and death due to any other cause